Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

REVEALED: Altimmune earnings perspective return on capital employed - The Real Truth

According to Benzinga Pro data, during Q4, Altimmune (NASDAQ:ALT) posted sales of $3.28 million. Earnings were up 28.71%, but Altimmune still reported an overall loss of $23.89 million. In Q3, Altimmune brought in $200.00 thousand in sales but lost $33.51 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.